Search Results

This submission is for Etest Doripenem for MIC determinations across 0.002-32 µg/mL with Gram negative aerobic bacteria such as Enterchacteriaceae, Accretobacer baumanii, Pseudomonas aeraginesa and Gram negative anaerobic bacteria such as Bacteroides aacae, B. fragilis, B.thetaiotaorracron, B. uniformis and B. ulgatus.

Etest is a quantitative technique for determination of antimicrobial susceptibility of both nonfastidious Gram negative and Gram positive aerobic bacteria such as Enterchaceriane, Pseudomnas, Staphylococus and Enteroxous species and fastidious bacteria, such as anaerobes, N. gonombeae, S. preumoniae, Streptoxous and Haemophilus species. The system comprises a predelined antibiotic gradient which is used to determine the Minimum Inhibitory Concentration (MIC) in ug/ mL of different antimicrobial agents against microorganisms as tested on agar using overnight incubation.

Not Found

This FDA 510(k) clearance letter pertains to the administrative process of marketing the Etest® Antimicrobial Susceptibility Test for Doripenem, rather than a detailed scientific study report. Therefore, much of the requested information about acceptance criteria and study particulars is not present in this document.

However, based on the context of an antimicrobial susceptibility test and the information provided, we can infer some aspects and acknowledge the limitations:

1. A table of acceptance criteria and the reported device performance

This document does not contain a table of acceptance criteria or specific performance values for the Etest® Doripenem test. Such information would typically be found in the manufacturer's 510(k) submission itself (which this document is a response to), or in scientific publications. However, for a device like this, the acceptance criteria would generally revolve around:

• Essential Agreement (EA) with a reference method: The percentage of MIC values that are within ±1 dilution of the reference method.
• Categorical Agreement (CA) with a reference method: The percentage of isolates where the Etest interpretation (Susceptible, Intermediate, Resistant) matches the reference method's interpretation.
• Minor Errors (mE), Major Errors (ME), and Very Major Errors (VME): These refer to specific types of discordance between the test and reference method, particularly concerning clinical interpretation. The acceptable rates for these errors are usually defined by regulatory bodies (e.g., FDA, CLSI).

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

This information is not available in the provided document. A typical premarket submission for an antimicrobial susceptibility test would involve testing a substantial number of bacterial isolates (e.g., hundreds or even thousands) for each drug-bug combination, often collected from diverse geographical locations. The studies would predominantly be prospective.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

This information is not available in the provided document. For antimicrobial susceptibility testing, the "ground truth" (or reference method) is typically established by laboratory-based, standardized methods using trained microbiologists (e.g., broth microdilution or agar dilution). It's not usually based on expert consensus in the same way as, for example, reading medical images.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

This information is not available in the provided document. Adjudication methods are not typically relevant for establishing the "ground truth" for a microbial susceptibility test; the reference method itself serves as the standard.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

An MRMC study is not applicable to this type of device. The Etest is a diagnostic test for determining drug susceptibility, not an AI-assisted diagnostic imaging tool.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

The Etest is a manual, phenotypic test strip. It is not an algorithm, nor does it operate "standalone" in the sense of a software algorithm. Its performance is evaluated based on its interpretability by trained laboratory personnel against a recognized reference method.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

The "ground truth" for antimicrobial susceptibility testing is typically established using a standardized reference method, such as:

• Broth Microdilution (BMD): Considered the gold standard for MIC determination.
• Agar Dilution: Another standardized method for MIC determination.

These methods involve precise dilutions of the antimicrobial agent and inoculation with a standardized bacterial suspension.

8. The sample size for the training set

This information is not available in the provided document. The Etest method relies on a pre-defined antibiotic gradient within the strip, not a "training set" in the machine learning sense. However, the manufacturer would have conducted extensive internal development and validation studies to determine the appropriate gradient and how to interpret the ellipse.

9. How the ground truth for the training set was established

As noted above, there isn't a "training set" in the machine learning context for this device. The development of Etest strips generally involves:

• Careful preparation of the antibiotic gradient: Ensuring precise and stable concentrations along the strip.
• Extensive testing against known bacterial strains: Using reference methods (like BMD) to correlate the ellipse formed by the Etest strip with the actual MIC of the drug for those strains. This helps in establishing the interpretive breakpoints for susceptibility, intermediate, and resistance categories.

Ask a specific question about this device

This submission is for the addition of Tigeycline to the Etest® product range for MIC delemination across a concentration range of 0.016-256 ug/mL. In vitro susceptibility testing of Tigecycline is indicated for Gram positive and Gram negative aerobic bacteria such as Enterobacteriaceae, Pseudomonas, Staphylococcus and Entercococus species and S. pneumoniae and anaerobic bacteria.

Etest® is a quantitative technique for the determination of antimicrobial susceptibility of microorganisms as tested on agar using overnight incubation. The system comprises a predefined antibiotic gradient which is used to determine the Minimum Inhibitory Concentration (MIC) in ug/mL of antimicrobial agents against microorganisms. Etest® can be used to test non-fastidious Gram negative and Gram positive aerobic bacteria such as Enterobacteriaceae, Pseudomonas, Staphylococcus and Entercococus species and fastidious bacteria, such as S. pneumoniae, Haemophilus Species, N. gonorrhoeae, and anaerobes.

Not Found

Here's an analysis of the provided text to extract information about the Etest® Antimicrobial Susceptibility Test – Tigecycline, focusing on acceptance criteria and study details:

1. A table of acceptance criteria and the reported device performance

The provided text does not explicitly state specific quantitative acceptance criteria or the reported device performance in a clear, tabulated format. It is a 510(k) clearance letter, which confirms substantial equivalence to a predicate device rather than presenting detailed study results and acceptance criteria directly.

Typically, such studies would compare the Etest® results to a reference method (e.g., broth microdilution) and report metrics like Categorical Agreement (CA), Essential Agreement (EA), statistical correlation (e.g., R-squared), or percentages of minor, major, and very major errors. These quantitative measures would be compared against predefined acceptance criteria (e.g., CA ≥ 90%, Major Error

Ask a specific question about this device

For in vitro diagnostic use:

Etest is a quantitative technique for the determination of antimicrobial susceptublity of both nonfastidious Gram negative and Gram positive aerobic bacteria, such as Enterobacteriansmassess, fastidious Grain negative and Chain posts ro associal, such as anaerones, Prammonons, Staphyloocws, Gonorous and Haemophius species. The system comprises a predefined and high in and the Streportus, Goldential and Plannylims openion inhibitory concentration (MIC) in ug/ml of gradent which is used to determine the minimals and media by overnight incubation. (Original FDA clearance for Etest - file K913459/A)

This Etest 510(k) submission is for an additional antibiotic i.c. Etest for MIC deemination of This Etest 310(K) Submission is 10.016 - 256 µg/ml with E. faecalis and E. Jaeium (vancomycin-Daptomyen in the MIC faires of over including methicillin resistant strains), coagulase negative Staphylococcus spp. and ß-haemolytic Streptococcus spp.

Etest is a quantitative technique for the determination of antimicrobial susceptublity of both nonfastidious Gram negative and Gram positive aerobic bacteria, such as Enterobacteriansmassess, fastidious Grain negative and Chain posts ro associal, such as anaerones, Prammonons, Staphyloocws, Gonorous and Haemophius species. The system comprises a predefined and high in and the Streportus, Goldential and Plannylims openion inhibitory concentration (MIC) in ug/ml of gradent which is used to determine the minimals and media by overnight incubation.

This document is a 510(k) clearance letter from the FDA for a new Etest® Daptomycin antimicrobial susceptibility test. It does not contain information about acceptance criteria or a study that proves the device meets specific acceptance criteria in the manner you've requested for typical AI/diagnostic device applications.

The provided text is a regulatory clearance document, not a detailed study report. It indicates that the device has been found substantially equivalent to a legally marketed predicate device. The information you're asking for (e.g., sample sizes, expert qualifications, study methodologies, performance metrics like sensitivity/specificity) is usually found in a separate clinical study report, which is typically summarized in the 510(k) submission but not fully detailed in the clearance letter itself.

Therefore, I cannot populate the table or answer the specific questions based only on the text provided because it does not contain that level of detail.

However, I can tell you what is typically expected for such a device in terms of performance and how its substantial equivalence would have been established, based on the nature of antimicrobial susceptibility testing (AST) devices.

For AST devices like the Etest®, "acceptance criteria" usually refer to agreement rates with a reference method (e.g., broth microdilution or agar dilution). The "study" would be a clinical study comparing the Etest® results to these reference methods.

Here's how I would hypothetically complete your request for an AST device, based on common FDA requirements for such submissions, and indicate what is not present in the provided document:

Description of Acceptance Criteria and Study to Prove Device Meets Criteria

Device: Etest® Daptomycin 0.016-256 µg/mL

Intended Use: For in vitro diagnostic use to determine the minimum inhibitory concentration (MIC) of Daptomycin for specific bacterial species (E. faecalis, E. faecium, Staphylococcus spp., Streptococcus spp.).

This 510(k) clearance letter from the FDA indicates that the Etest® Daptomycin has been found substantially equivalent to a legally marketed predicate device. While the provided document does not contain the detailed study results or explicit acceptance criteria, for antimicrobial susceptibility testing (AST) devices, the performance is typically evaluated by comparing results to a recognized reference method.

Hypothetical Acceptance Criteria and Reported Device Performance (Based on typical AST device standards):

Ask a specific question about this device

For in vitro diagnostic use:

Etest is a quantitative technique for the determination of antimicrobial susceptibility of both nonfastidious Gram negative and Gram positive aerobic bacteria, such as Enterobacteriaxeae, Pseudomonas, Staphylooocus and Enteroous species and fastidious bacteria, such as anaerobes, Pneumooocus, Streptocous, Gonocous and Haemophilus species. The system comprises a predefined antibiotic gradient that is used to determine the minimum inhibitory concentration (MIC) in µg/ml of individual antibiotics against bacteria as tested on agar media by overnight incubation.

This 510(k) submission is for an additional drug for Etest for MIC determination of Gemifloxacin MIC 0.002 - 32 µg/ml with Enterobacteriaceae, S. pneumoniae and H. influenzae.

Not Found

This document is a 510(k) premarket notification decision letter from the FDA for the Etest® Gemifloxacin 0.002-32 µg/mL. This document is a regulatory approval, and as such, it does not contain the detailed study information required to answer the prompt.

Specifically, the document does not include:

1. A table of acceptance criteria and reported device performance.
2. Sample sizes or data provenance for a test set.
3. Information on experts used to establish ground truth or their qualifications.
4. Adjudication methods.
5. Results of a multi-reader multi-case (MRMC) comparative effectiveness study.
6. Results of a standalone algorithm performance study.
7. The type of ground truth used.
8. Sample size for the training set.
9. How ground truth for the training set was established.

The letter explicitly states: "We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976..." This means the device was approved based on its substantial equivalence to a predicate device, not necessarily on a new, comprehensive study detailed within this document. The "Indications for Use" section further clarifies that the submission is "for an additional drug for Etest for MIC determination of Gemifloxacin MIC 0.002 - 32 µg/ml with Enterobacteriaceae, S. pneumoniae and H. influenzae."

To obtain the requested information, one would need to refer to the full 510(k) submission document (K042390) itself, which would contain the study results and details that supported the substantial equivalence claim.

Ask a specific question about this device

Etest® is an agar-based gradient technique for quantitative antifungal susceptibility testing of Candida species. It uses a predefined concentration gradient of the specific antifungal agent to determine the Minimum Inhibitory Concentration (MIC) in ug/mL inhibiting the growth of the test organism under defined conditions. This 510k submission is for an application for in wire diagnostic use of Etest for MIC determination of fluconazole, itraconazole and flucytosine with Candida species.

Not Found

The provided document is an FDA 510(k) clearance letter for an antimicrobial susceptibility test. It does not contain the detailed study information, acceptance criteria, or performance data typically found in a clinical study report or a more comprehensive submission document.

Therefore, I cannot extract the information required in the prompt (acceptance criteria, reported device performance, sample size, data provenance, ground truth establishment, expert qualifications, adjudication methods, MRMC studies, standalone performance, training set details) from this letter.

The letter primarily confirms that the device is substantially equivalent to a legally marketed predicate device for the stated indications for use. It doesn't present the underlying data or the specific criteria against which that data was evaluated.

Ask a specific question about this device

For in vitro diagnostic use:

Etest is a quantitative technique for the determination of antimicrobial susceptibility of both non-fastidious Gram negative and Gram positive aerobic bacteria, such as Enterobacteriaceae, Pseudomonas, Staphylococcus and Enterococcus species and fastidious bacteria, such as anaerobes, Pneumococcus, Streptococcus, Gonococcus and Haemophilus species. The system comprises a predefined antibiotic gradient which is used to determine the minimum inhibitory concentration (MIC) in ug/ml of individual antibiotics against bacteria as tested on agar media by overnight incubation.

This Etest 510(k) application is for MIC determination of Cefditoren in the range of 0.002 - 32 µg/ml with S. pneumoniae (penicillin susceptible strains only) and H. influenzae.

Not Found

This document is a 510(k) clearance letter from the FDA for a device called "Etest® Cefditoren." It does not contain information about acceptance criteria, device performance, or details of a study as requested. The content only confirms that the device is substantially equivalent to legally marketed predicate devices and can proceed to market.

Therefore, I cannot provide the requested information based solely on the provided text. The document is essentially a regulatory approval notice, not a study report.

Ask a specific question about this device

For in vitro diagnostic use: Etest is a quantitative technique for the determination of antimicrobial susceptibility of both aerobic bacteria, such as Enterobacteriaceae, non-fastidious Gram negative and Enterococcus species and fastidious bacteria, such as Pseudomonas, Staphylococcus and Enterococcus and Haemophilus species. The system comprises a preformed antibiotics against bacteria as tested on agar media by overnight incubation. This Etest 510(k) application is for MIC determination of Ertapenem in the range of 0.002-32 μg/mL against Enterobacteriaceae, E. coli, K. pneumoniae, S. aureus (methicillin susceptible strains), S. pneumoniae (penicillin susceptible strains), S. agalactiae, S. pyogenes, H. influenzae (β-lactamase negative strains), Bacteroides spp, Prevotella bivia, P. asaccharolytica and Peptostreptococcus spp.

Not Found

The provided document is a 510(k) clearance letter from the FDA for the Etest® Ertapenem device, an antimicrobial susceptibility test. While it indicates that the device has been found substantially equivalent to a predicate device, it does not contain the detailed study information, acceptance criteria, or performance data that would typically be found in a comprehensive submission.

Therefore, I cannot extract the requested information. The letter only broadly states that the device is "substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices."

To answer your request, I would need access to the full 510(k) submission document, which would include the study design, acceptance criteria, test results, and other details about the device's performance.

Ask a specific question about this device

Ask a specific question about this device

Ask a specific question about this device

Ask a specific question about this device